Pancreatic islet allograft in spleen with immunosuppression with cyclosporine. Experimental model in dogs.
OBJECTIVE
To study the functional behavior of the allograft with immunosuppression of pancreatic islets in the spleen.


METHODS
Five groups of 10 Mongrel dogs were used: Group A (control) underwent biochemical tests; Group B underwent total pancreatectomy; Group C underwent total pancreatectomy and pancreatic islet autotransplant in the spleen; Group D underwent pancreatic islet allograft in the spleen without immunosuppressive therapy; Group E underwent pancreatic islet allograft in the spleen and immunosuppression with cyclosporine. All of the animals with grafts received pancreatic islets prepared by the mechanical-enzymatic method - stationary collagenase digestion and purification with dextran discontinuous density gradient, implanted in the spleen.


RESULTS
The animals with autotransplant and those with allografts with immunosuppression that became normoglycemic showed altered results of intravenous tolerance glucose (p < 0.001) and peripheral and splenic vein plasmatic insulin levels were significantly lower (p < 0.001) in animals that had allografts with immunosuppression than in those with just autotransplants.


CONCLUSIONS
In the animals with immunosuppression with cyclosporine subjected to allograft of pancreatic islets prepared with the mechanical-enzymatic preparation method (stationary collagenase digestion and purification with dextran discontinuous density gradient), the production of insulin is decreased and the response to intravenous glucose is altered.
Department of Surgery, Faculty of Medicine of ABC, Santo Andre, SP, Brazil. jaqueswaisberg@uol.com.br
Jaques
J
Waisberg
Charles Benjamin
CB
Neff
Daniel Reis
DR
Waisberg
Demetrius
D
Germini
José Eduardo
JE
Gonçalves
Arnaldo
A
Zanotto
Manlio Basilio
MB
Speranzini
D000818:Animals; D001786:Blood Glucose / Q000032:analysis; D016572:Cyclosporine / Q000494:pharmacology*; D004195:Disease Models, Animal; D004285:Dogs; D005215:Fasting / Q000097:blood; D005951:Glucose Tolerance Test; D006943:Hyperglycemia / Q000097:blood; D007165:Immunosuppression Therapy / Q000379:methods; D007166:Immunosuppressive Agents / Q000494:pharmacology*; D007328:Insulin / Q000096:biosynthesis / Q000097:blood; D007515:Islets of Langerhans / Q000187:drug effects; D016381:Islets of Langerhans Transplantation / Q000379:methods* / Q000502:physiology; D008297:Male; D010180:Pancreatectomy / Q000379:methods; D013154:Spleen; D014182:Transplantation, Autologous; D014184:Transplantation, Homologous; D016896:Treatment Outcome
D001786:Blood Glucose; D007166:Immunosuppressive Agents; D007328:Insulin; D016572:Cyclosporine